Pure Global | Brazil's ANVISA Shock: Navigating the New UDI Traceability Maze for MedTech

This week, we dissect a sudden and significant regulatory enforcement shift from Brazil's ANVISA. The agency has accelerated the implementation of its comprehensive UDI traceability system for high-risk medical devices, a key part of its 2026-2027 agenda to harmonize with global standards. This move is catching many international manufacturers off guard, creating immediate challenges for market access and post-market compliance. We explore the concrete implications of this accelerated timeline, from rejected submissions due to data inconsistencies to new, stringent requirements for adverse event reporting. Consider a company that has spent years preparing its Class IV device for the Brazilian market. They believe their dossier is perfect, but their submission is rejected on day one. The reason is not a failure in the device's clinical data, but an administrative error in the UDI database submission, a new and complex requirement. This single misstep could delay their launch by over six months, costing millions in potential revenue. **Key Takeaways:** * What are the exact database requirements for the new UDI submissions under ANVISA's accelerated timeline? * How does this UDI enforcement align with the broader EU MDR harmonization trend in Brazil? * Which specific device classes are most at risk for submission delays right now? * What are the new post-market surveillance reporting requirements involving UDI data? * How can you validate your UDI data for ANVISA's system before making a formal submission? * What are the most common mistakes manufacturers are making with the new UDI requirements? * How should this change impact your budget and timeline for entering the Brazilian market? Navigating unexpected regulatory hurdles like these is where Pure Global excels. We provide end-to-end regulatory consulting for MedTech and IVD companies, leveraging our local expertise in Brazil and over 30 other markets. From developing an updated regulatory strategy to managing complex database submissions and ensuring post-market compliance, we streamline your path to market. Don't let regulatory surprises derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market access.